



December 20, 2023
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Change in Duties of Directors

December 20, 2023 -- [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; Chairman and President: Shin Ashida; "JCR") hereby announces that its Board of Directors resolved at a meeting held today to change directors' duties changes as follows.

1. Change in Duties of Directors (As of December 20, 2023)

The Management Team composed of Directors, Senior Corporate Officers and some Corporate Officers will make certain changes to the duties of directors to further accelerate global development.

Name	New Area of Supervision	Current Area of Supervision
Mathias Schmidt, PD, Ph.D. (Vice President, ArmaGen, Inc. CEO JCR USA, Inc. President and CEO)	Patient Association Response ArmaGen, Inc. CEO JCR USA, Inc. President and Business development and IR fields, excluding Japan	Clinical development (overall supervision) ArmaGen, Inc. CEO JCR USA, Inc. President and CEO Business development and IR fields, excluding Japan
Anne Bechet (JCR Europe B.V. General Manager)	Development (Acting Officer) JCR Europe B.V. General Manager	JCR Europe B.V. General Manager

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products News Release in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###